# US 2018/0021378 A1 · Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021378 A1
- Document ID: US20180021378A1
- Status: Published application
- Kind: A1
- Application number: 15/541,006
- Filed: 2015-12-30
- Published: 2018-01-25
- Earliest claimed: 2014-12-31
- Assignees: Anthrogenesis Corporation
- Applicants: Anthrogenesis Corporation
- Inventors: Lin KANG; Xiaokui ZHANG; Jeffrey HARRIS; Vladimir JANKOVIC
- Web page: https://patentgrep.com/patent/US20180021378A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2887: {against CD20}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/6006: {Cells}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/91: Heparin
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2506/11: from blood or immune system cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, comprising:
(a) administering to said subject an isolated population of natural killer (NK) cells or a pharmaceutical composition thereof; and
(b) administering to said subject a second agent or a pharmaceutical composition thereof, wherein said second agent can be used to treat said cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to a tumor-associated antigen (TAA).

### Claim 3 (depends on 2)

The method of claim 2, wherein the antibody is a monoclonal antibody.

### Claim 4 (depends on 2, 3)

The method of claim 2 or 3, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, and GD2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to a tumor microenvironment-associated antigen (TMAA).

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody is a monoclonal antibody.

### Claim 7 (depends on 5, 6)

The method of claim 5 or 6, wherein the TMAA is selected from the group consisting of VEGF-A, EGF, PDGF, IGF, and bFGF.

### Claim 8 (depends on 1)

The method of claim 1, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to and antagonizes the activity of an immune checkpoint protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody is a monoclonal antibody.

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the immune checkpoint protein is selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-L2, and LAG-3.

### Claim 11 (depends on 1)

The method of claim 1, wherein the second agent is a bispecific killer cell engager (BiKE).

### Claim 12 (depends on 11)

The method of claim 11, wherein the BiKE comprises a first single chain variable fragment (scFv) that specifically binds to a TAA.

### Claim 13 (depends on 12)

The method of claim 12, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, and GD2.

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11-13, wherein the BiKE comprises a second scFv that specifically binds to CD16

### Claim 15 (depends on 1)

The method of claim 1, wherein the second agent is an anti-inflammatory agent.

### Claim 16 (depends on 1)

The method of claim 1, wherein the second agent is an immunomodulatory agent.

### Claim 17 (depends on 1)

The method of claim 1, wherein the second agent is a cytotoxic agent.

### Claim 18 (depends on 1)

The method of claim 1, wherein the second agent is a cancer vaccine.

### Claim 19 (depends on 1)

The method of claim 1, wherein the second agent is a chemotherapeutic.

### Claim 20 (depends on 1)

The method of claim 1, wherein the second agent is an HDAC inhibitor.

### Claim 21 (depends on 1)

The method of claim 1, wherein the second agent is an siRNA.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered before the second agent or a pharmaceutical composition thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered after the second agent or a pharmaceutical composition thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered at the same time as the second agent or a pharmaceutical composition thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the step of administering to said subject a second agent or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the step of administering to said subject a second agent or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the NK cells are fucosylated on the cell surface.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in a single dose.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the second agent or a pharmaceutical composition thereof is administered in a single dose.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the second agent or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 34

A method of treating a cancer in a subject in need thereof, comprising administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof, wherein the NK cells comprise a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and optionally a co-stimulatory domain.

### Claim 35 (depends on 34)

The method of claim 34, wherein the CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and a co-stimulatory domain.

### Claim 36 (depends on 34, 35)

The method of claim 34 or 35, wherein the NK cells comprising the CAR are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the CAR.

### Claim 37 (depends on 34, 35, 36)

The method of any one of claims 34-36, wherein the extracellular domain is an antigen binding domain.

### Claim 38 (depends on 37)

The method of claim 37, wherein the antigen binding domain is an scFv domain.

### Claim 39 (depends on 37, 38)

The method of claim 37 or 38, wherein the antigen binding domain specifically binds to a TAA.

### Claim 40 (depends on 39)

The method of claim 39, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, and CS-1.

### Claim 41 (depends on 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 34-40, wherein the intracellular stimulatory domain is a CD3 zeta signaling domain.

### Claim 42 (depends on 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 34-41, wherein the co-stimulatory domain comprises the intracellular domain of CD28, 4-1BB, PD-1, OX40, CTLA-4, NKp46, NKp44, NKp30, DAP10 or DAP12.

### Claim 43

A method of treating a cancer in a subject in need thereof, comprising administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof, wherein the NK cells comprise a homing receptor.

### Claim 44 (depends on 43)

The method of claim 43, wherein the NK cells comprising the homing receptor are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the homing receptor.

### Claim 45 (depends on 43, 44)

The method of claim 43 or 44, wherein the homing receptor is a chemotactic receptor,

### Claim 46 (depends on 45)

The method of claim 45, wherein the chemotactic receptor is selected from the group consisting of CXCR4, VEGFR2, and CCR7.

### Claim 47

A method of treating a cancer in a subject in need thereof, comprising administering to said subject an isolated population of Natural Killer (NK) cells or a pharmaceutical composition thereof, wherein the NK cells comprise a chimeric antigen receptor (CAR) and a homing receptor, wherein said CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and optionally a co-stimulatory domain.

### Claim 48 (depends on 47)

The method of claim 47, wherein the CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and a co-stimulatory domain.

### Claim 49 (depends on 47, 48)

The method of claim 47 or 48, wherein the NK cells comprising the CAR and the homing receptor are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the CAR.

### Claim 50 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the NK cells comprising the CAR and the homing receptor are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the homing receptor.

### Claim 51 (depends on 47, 48, 49, 50)

The method of any one of claims 47-50, wherein the extracellular domain is an antigen binding domain.

### Claim 52 (depends on 51)

The method of claim 51, wherein the antigen binding domain is an scFv domain.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the antigen binding domain specifically binds to a TAA.

### Claim 54 (depends on 53)

The method of claim 53, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, and CS-1.

### Claim 55 (depends on 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 47-54, wherein the intracellular stimulatory domain is a CD3 zeta signaling domain.

### Claim 56 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 47-55, wherein the co-stimulatory domain comprises the intracellular domain of CD28, 4-1BB, PD-1, OX40, CTLA-4, NKp46, NKp44, NKp30, DAP10 or DAP12.

### Claim 57 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 47-56, wherein the homing receptor is a chemotactic receptor,

### Claim 58 (depends on 57)

The method of claim 57, wherein the chemotactic receptor is selected from the group consisting of CXCR4, VEGFR2, and CCR7.

### Claim 59 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 34-58, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 60 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 34-59, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 61 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 34-60, wherein the NK cells are fucosylated on the cell surface.

### Claim 62 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 34-61, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in a single dose.

### Claim 63 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 34-61, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein the cancer is a hematological cancer.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein the cancer is a solid tumor.

### Claim 66

A method of treating a viral infection in a subject in need thereof, comprising:
(a) administering to said subject an isolated population of Natural Killer (NK) cells or a pharmaceutical composition thereof; and
(b) administering to said subject a second agent or a pharmaceutical composition thereof, wherein said second agent can be used to treat said viral infection.

### Claim 67 (depends on 66)

The method of claim 66, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to and antagonizes the activity of an immune checkpoint protein.

### Claim 68 (depends on 67)

The method of claim 67, wherein the antibody is a monoclonal antibody.

### Claim 69 (depends on 67, 68)

The method of claim 67 or 68, wherein the immune checkpoint protein is selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-L2, and LAG-3.

### Claim 70 (depends on 66)

The method of claim 66, wherein the second agent is a bispecific killer cell engager (BiKE).

### Claim 71 (depends on 66, 67, 68, 69, 70)

The method of any one of claims 66-70, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered before the second agent or a pharmaceutical composition thereof.

### Claim 72 (depends on 66, 67, 68, 69, 70)

The method of any one of claims 66-70, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered after the second agent or a pharmaceutical composition thereof.

### Claim 73 (depends on 66, 67, 68, 69, 70)

The method of any one of claims 66-70, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered at the same time as the second agent or a pharmaceutical composition thereof.

### Claim 74 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 75 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 66-74, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 76 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 66-75, wherein the step of administering to said subject a second agent or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 77 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 66-76, wherein the step of administering to said subject a second agent or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 78 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 66-77, wherein the NK cells are fucosylated on the cell surface.

### Claim 79 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 66-78, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in a single dose.

### Claim 80 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 66-78, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 81 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 66-80, wherein the second agent or a pharmaceutical composition thereof is administered in a single dose.

### Claim 82 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 66-80, wherein the second agent or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 83

A method of treating a viral infection in a subject in need thereof, comprising administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof, wherein the NK cells comprise a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and optionally a co-stimulatory domain.

### Claim 84 (depends on 83)

The method of claim 83, wherein the CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and a co-stimulatory domain.

### Claim 85 (depends on 83, 84)

The method of claim 83 or 84, wherein the NK cells comprising the CAR are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the CAR.

### Claim 86 (depends on 83, 84, 85)

The method of any one of claims 83-85, wherein the extracellular domain is an antigen binding domain.

### Claim 87 (depends on 86)

The method of claim 86, wherein the antigen binding domain is an scFv domain.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The method of any one of claims 83-87, wherein the intracellular stimulatory domain is a CD3 zeta signaling domain.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any one of claims 83-88, wherein the co-stimulatory domain comprises the intracellular domain of CD28, 4-1BB, PD-1, OX40, CTLA-4, NKp46, NKp44, NKp30, DAP10 or DAP12.

### Claim 90

A method of treating a viral infection in a subject in need thereof, comprising administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof, wherein the NK cells comprise a homing receptor.

### Claim 91 (depends on 90)

The method of claim 90, wherein the NK cells comprising the homing receptor are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the homing receptor.

### Claim 92 (depends on 90, 91)

The method of claim 90 or 91, wherein the homing receptor is a chemotactic receptor,

### Claim 93 (depends on 92)

The method of claim 92, wherein the chemotactic receptor is selected from the group consisting of CXCR4, VEGFR2, and CCR7.

### Claim 94

A method of treating a viral infection in a subject in need thereof, comprising administering to said subject an isolated population of Natural Killer (NK) cells or a pharmaceutical composition thereof, wherein the NK cells comprise a chimeric antigen receptor (CAR) and a homing receptor, wherein said CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and optionally a co-stimulatory domain.

### Claim 95 (depends on 94)

The method of claim 94, wherein the CAR comprises an extracellular domain, a transmembrane domain, an intracellular stimulatory domain, and a co-stimulatory domain.

### Claim 96 (depends on 94, 95)

The method of claim 94 or 95, wherein the NK cells comprising the CAR and the homing receptor are derived from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the CAR.

### Claim 97 (depends on 94, 95, 96)

The method of any one of claims 94-96, wherein the NK cells are produced from CD34+ hematopoietic stem cells (HSCs) that are engineered to express the homing receptor.

### Claim 98 (depends on 94, 95, 96, 97)

The method of any one of claims 94-97, wherein the extracellular domain is an antigen binding domain.

### Claim 99 (depends on 98)

The method of claim 98, wherein the antigen binding domain is an scFv domain.

### Claim 100 (depends on 94, 95, 96, 97, 98, 99)

The method of any one of claims 94-99, wherein the intracellular stimulatory domain is a CD3 zeta signaling domain.

### Claim 101 (depends on 94, 95, 96, 97, 98, 99, 100)

The method of any one of claims 94-100, wherein the co-stimulatory domain comprises the intracellular domain of CD28, 4-1BB, PD-1, OX40, CTLA-4, NKp46, NKp44, NKp30, DAP10 or DAP12.

### Claim 102 (depends on 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 94-101, wherein the homing receptor is a chemotactic receptor,

### Claim 103 (depends on 102)

The method of claim 102, wherein the chemotactic receptor is selected from the group consisting of CXCR4, VEGFR2, and CCR7.

### Claim 104 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any one of claims 83-103, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is by injection, infusion, intravenous (IV) administration, intrafemoral administration, or intratumor administration.

### Claim 105 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The method of any one of claims 83-104, wherein the step of administering to said subject an isolated population of NK cells or a pharmaceutical composition thereof is performed with a devise, a matrix, or a scaffold.

### Claim 106 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any one of claims 83-105, wherein the NK cells are fucosylated on the cell surface.

### Claim 107 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 83-106, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in a single dose.

### Claim 108 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 83-106, wherein the isolated population of NK cells or a pharmaceutical composition thereof is administered in multiple doses.

### Claim 109 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The method of any one of claims 1-13 and 15-108, wherein the NK cells are placental intermediate natural killer (PiNK) cells.

### Claim 110 (depends on 1, 108)

The method of any one of claims 1-108, wherein the NK cells are activated NK cells.

### Claim 111 (depends on 1, 108)

The method of any one of claims 1-108, wherein the NK cells are Three-Step Process NK (TSPNK) cells.

### Claim 112 (depends on 111)

The method of claim 111, wherein the TSPNK cells are NK progenitor cells.

### Claim 113 (depends on 108)

The method of claim 108, wherein the PiNK cells are derived from placental cells.

### Claim 114 (depends on 113)

The method of claim 113, wherein the placental cells are obtained from placental perfusate.

### Claim 115 (depends on 113)

The method of claim 113, wherein the placental cells are obtained from placental tissue that has been mechanically and/or enzymatically disrupted.

### Claim 116 (depends on 110)

The method of claim 110, wherein the activated NK cells are produced by a process comprising:
(a) seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7), wherein said IL-15 and optional SCF and IL-7 are not comprised within an undefined component of said medium, such that the population expands, and a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and
(b) expanding the cells from the step (a) in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells.

### Claim 117 (depends on 110)

The method of claim 110, wherein the activated NK cells are produced by a process comprising: expanding a population of hematopoietic stem or progenitor cells in a first medium comprising one or more of stem cell factor (SCF), interleukin-7 (IL-7) and interleukin-15 (IL-15), and wherein said SCF, IL-7 and IL-15 are not comprised within an undefined component of said medium, and wherein a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and wherein a second step of said method comprises expanding the cells from the first step in a second medium comprising interleukin-2 (IL-2), to produce activated NK cells.

### Claim 118 (depends on 116)

The method of claim 116, wherein the first medium further comprises one or more of Fms-like-tyrosine kinase 3 ligand (Flt3-L), thrombopoietin (Tpo), interleukin-2 (IL-2), or heparin.

### Claim 119 (depends on 118)

The method of claim 118, wherein the first medium further comprises fetal bovine serum or human serum.

### Claim 120 (depends on 118)

The method of claim 118, wherein the SCF is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 121 (depends on 118)

The method of claim 118, wherein the Flt3-L is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 122 (depends on 118)

The method of claim 118, wherein the IL-2 is present at a concentration of about 50 to about 1500 IU/mL in the first medium.

### Claim 123 (depends on 118)

The method of claim 118, wherein the IL-7 is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 124 (depends on 118)

The method of claim 118, wherein the IL-15 is present at a concentration 1 to about 150 ng/mL in the first medium.

### Claim 125 (depends on 118)

The method of claim 118, wherein the Tpo is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 126 (depends on 118)

The method of claim 118, wherein the heparin is present at a concentration of about 0.1 to about 30 U/mL in the first medium.

### Claim 127 (depends on 116)

The method of claim 116, wherein said IL-2 in the second step is present at a concentration 50 to about 1500 IU/mL in the second medium.

### Claim 128 (depends on 116)

The method of claim 116, wherein said second medium additionally comprises one or more of fetal calf serum (FCS), transferrin, insulin, ethanolamine, oleic acid, linoleic acid, palmitic acid, bovine serum albumin (BSA) and phytohemagglutinin.

### Claim 129 (depends on 116)

The method of claim 116, wherein the hematopoietic stem or progenitor cells are CD34+.

### Claim 130 (depends on 116)

The method of claim 116, wherein the hematopoietic stem or progenitor cells comprise hematopoietic stem or progenitor cells from human placental perfusate and hematopoietic stem or progenitor cells from umbilical cord, wherein said placental perfusate and said umbilical cord blood are from the same placenta.

### Claim 131 (depends on 116)

The method of claim 116, wherein the feeder cells in step (b) comprise mitomycin C-treated peripheral blood mononuclear cells (PBMC), K562 cells or tissue culture-adherent stem cells.

### Claim 132 (depends on 116)

The method of claim 116, wherein the NK cells are CD3−CD56+CD16−.

### Claim 133 (depends on 132)

The method of claim 132, wherein the NK cells are additionally CD94+CD117+.

### Claim 134 (depends on 132)

The method of claim 132, wherein the NK cells are additionally CD161−.

### Claim 135 (depends on 132)

The method of claim 132, wherein the NK cells are additionally NKG2D+.

### Claim 136 (depends on 132)

The method of claim 132, wherein the NK cells are additionally NKp46+.

### Claim 137 (depends on 132)

The method of claim 132, wherein the NK cells are additionally CD226+.

### Claim 138 (depends on 111, 112)

The method of claim 111 or 112, wherein the TSPNK cells are produced by a process comprising:
(a) culturing hematopoietic stem cells or progenitor cells in a first medium comprising Flt3L, TPO, SCF, IL-7, G-CSF, IL-6 and GM-CSF;
(b) subsequently culturing said cells in a second medium comprising Flt3L, SCF, IL-15, and IL-7, IL-17 and IL-15, G-CSF, IL-6 and GM-CSF; and
(c) subsequently culturing said cells in a third medium comprising SCF, IL-15, IL-7, IL-2, G-CSF, IL-6 and GM-CSF.

### Claim 139 (depends on 138)

The method of claim 138, wherein the duration of culturing step (a) is 7-9 days, wherein the duration of culturing step (b) is 5-7 days, and wherein the duration of culturing step (c) is 5-9 days.

### Claim 140 (depends on 138)

The method of claim 138, wherein the duration of culturing step (a) is 7-9 days, wherein the duration of culturing step (b) is 5-7 days, and wherein the duration of culturing step (c) is 21-35 days.

### Claim 141 (depends on 138, 139)

The method of claim 138, 139, or 140 wherein the hematopoietic stem or progenitor cells used in the process are CD34+.

### Claim 142 (depends on 138, 139)

The method of claim 138, 139, or 140 wherein the hematopoietic stem or progenitor cells comprise hematopoietic stem or progenitor cells from human placental perfusate and hematopoietic stem or progenitor cells from umbilical cord, wherein said placental perfusate and said umbilical cord blood are from the same placenta.

### Claim 143 (depends on 138, 139, 140, 141, 142)

The method of any one of claims 138-142, wherein CD34− cells comprise more than 80% of the TSPNK cells at the end of step (a).

### Claim 144 (depends on 138, 139, 140, 141, 142, 143)

The method of any one of claims 138-143, wherein the TSPNK cells comprise no more than 40% CD3− CD56+ cells.

### Claim 145 (depends on 138, 139, 140, 141, 142, 143, 144)

The method of any one of claims 138-144, wherein the TSPNK cells comprise cells which are CD52+ CD117+.

### Claim 146 (depends on 1, 108)

The method of any one of claims 1-108, wherein the NK cells are produced by a process comprising:
(a) culturing hematopoietic stem or progenitor cells in a first medium comprising a stem cell mobilizing agent and thrombopoietin (Tpo) to produce a first population of cells;
(b) culturing the first population of cells in a second medium comprising a stem cell mobilizing agent and interleukin-15 (IL-15), and lacking Tpo, to produce a second population of cells; and
(c) culturing the second population of cells in a third medium comprising IL-2 and IL-15, and lacking a stem cell mobilizing agent and LMWH, to produce a third population of cells;
wherein the third population of cells comprises natural killer cells that are CD56+, CD3−, CD16− or CD16+, and CD94+ or CD94−, and wherein at least 80% of the natural killer cells are viable.

### Claim 147 (depends on 1, 146)

The method of any one of claims 1-146, wherein the subject is a human.

### Claim 148

A kit for treating a cancer in a subject in need thereof, comprising:
(a) an isolated population of NK cells or a pharmaceutical composition thereof; and
(b) a second agent or a pharmaceutical composition thereof, wherein said second agent can be used to treat said cancer.

### Claim 149 (depends on 148)

The kit of claim 148, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to a tumor-associated antigen (TAA).

### Claim 150 (depends on 149)

The kit of claim 149, wherein the antibody is a monoclonal antibody.

### Claim 151 (depends on 149, 150)

The kit of claim 149 or 150, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, and GD2.

### Claim 152 (depends on 148)

The kit of claim 148, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to a tumor microenvironment-associated antigen (TMAA).

### Claim 153 (depends on 152)

The kit of claim 152, wherein the antibody is a monoclonal antibody.

### Claim 154 (depends on 152, 153)

The kit of claim 152 or 153, wherein the TMAA is selected from the group consisting of VEGF-A, EGF, PDGF, IGF, and bFGF.

### Claim 155 (depends on 148)

The kit of claim 148, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to and antagonizes the activity of an immune checkpoint protein.

### Claim 156 (depends on 155)

The kit of claim 155, wherein the antibody is a monoclonal antibody.

### Claim 157 (depends on 155, 156)

The kit of claim 155 or 156, wherein the immune checkpoint protein is selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-L2, and LAG-3.

### Claim 158 (depends on 148)

The method of claim 148, wherein the second agent is a bispecific killer cell engager (BiKE).

### Claim 159 (depends on 158)

The kit of claim 158, wherein the BiKE comprises a first single chain variable fragment (scFv) that specifically binds to a TAA.

### Claim 160 (depends on 159)

The kit of claim 159, wherein the TAA is selected from the group consisting of CD123, CLL-1, CD38, CS-1, CD138, ROR1, FAP, MUC1, PSCA, EGFRvIII, EPHA2, and GD2.

### Claim 161 (depends on 158, 159, 160)

The kit of any one of claims 158-160, wherein the BiKE comprises a second scFv that specifically binds to CD16.

### Claim 162 (depends on 148)

The kit of claim 148, wherein the second agent is an anti-inflammatory agent.

### Claim 163 (depends on 148)

The kit of claim 148, wherein the second agent is an immunomodulatory agent.

### Claim 164 (depends on 148)

The kit of claim 148, wherein the second agent is a cytotoxic agent.

### Claim 165 (depends on 148)

The kit of claim 148, wherein the second agent is a cancer vaccine.

### Claim 166 (depends on 148)

The kit of claim 148, wherein the second agent is a chemotherapeutic.

### Claim 167 (depends on 148)

The kit of claim 148, wherein the second agent is an HDAC inhibitor.

### Claim 168 (depends on 148)

The kit of claim 148, wherein the second agent is a siRNA.

### Claim 169 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168)

The kit of any one of claims 148-168, wherein the cancer is a hematological cancer.

### Claim 170 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168)

The method of any one of claims 148-168, wherein the cancer is a solid tumor.

### Claim 171

A kit for treating a viral infection in a subject in need thereof, comprising:
(a) an isolated population of Natural Killer (NK) cells or a pharmaceutical composition thereof; and
(b) a second agent or a pharmaceutical composition thereof, wherein said second agent can be used to treat said viral infection.

### Claim 172 (depends on 171)

The kit of claim 171, wherein the second agent is an antibody or antigen binding fragment thereof that specifically binds to and antagonizes the activity of an immune checkpoint protein.

### Claim 173 (depends on 172)

The kit of claim 172, wherein the antibody is a monoclonal antibody.

### Claim 174 (depends on 171, 172)

The kit of claim 171 or 172, wherein the immune checkpoint protein is selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-L2, and LAG-3.

### Claim 175 (depends on 171)

The method of claim 171, wherein the second agent is a bispecific killer cell engager (BiKE).

### Claim 176 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The kit of any one of claims 148-160 and 162-175, wherein the NK cells are placenta intermediate natural killer (PiNK) cells.

### Claim 177 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The kit of any one of claims 148-175, wherein the NK cells are activated NK cells.

### Claim 178 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The kit of any one of claims 148-175, wherein the NK cells are TSPNK cells.

### Claim 179 (depends on 178)

The kit of claim 178, wherein the TSPNK cells are NK progenitor cells.

### Claim 180 (depends on 176)

The kit of claim 176, wherein the PiNK cells are derived from placental cells.

### Claim 181 (depends on 180)

The kit of claim 180 wherein the placental cells are obtained from placental perfusate.

### Claim 182 (depends on 181)

The kit of claim 181, wherein the placental cells are obtained from placental tissue that has been mechanically and/or enzymatically disrupted.

### Claim 183 (depends on 177)

The kit of claim 177, wherein the activated NK cells are produced by a process comprising:
(a) seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7), wherein said IL-15 and optional SCF and IL-7 are not comprised within an undefined component of said medium, such that the population expands, and a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and
(b) expanding the cells from the step (a) in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells.

### Claim 184 (depends on 177)

The kit of claim 177, wherein the activated NK cells are produced by a process comprising: expanding a population of hematopoietic stem or progenitor cells in a first medium comprising one or more of stem cell factor (SCF), interleukin-7 (IL-7) and interleukin-15 (IL-15), and wherein said SCF, IL-7 and IL-15 are not comprised within an undefined component of said medium, and wherein a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and wherein a second step of said method comprises expanding the cells from the first step in a second medium comprising interleukin-2 (IL-2), to produce activated NK cells.

### Claim 185 (depends on 183)

The kit of claim 183, wherein the first medium further comprises one or more of Fms-like-tyrosine kinase 3 ligand (Flt3-L), thrombopoietin (Tpo), interleukin-2 (IL-2), or heparin.

### Claim 186 (depends on 185)

The kit of claim 185, wherein the first medium further comprises fetal bovine serum or human serum.

### Claim 187 (depends on 185)

The kit of claim 185, wherein the SCF is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 188 (depends on 185)

The kit of claim 185, wherein the Flt3-L is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 189 (depends on 185)

The kit of claim 185, wherein the IL-2 is present at a concentration of about 50 to about 1500 IU/mL in the first medium.

### Claim 190 (depends on 185)

The kit of claim 185, wherein the IL-7 is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 191 (depends on 185)

The kit of claim 185, wherein the IL-15 is present at a concentration 1 to about 150 ng/mL in the first medium.

### Claim 192 (depends on 185)

The kit of claim 185, wherein the Tpo is present at a concentration of about 1 to about 150 ng/mL in the first medium.

### Claim 193 (depends on 185)

The kit of claim 185, wherein the heparin is present at a concentration of about 0.1 to about 30 U/mL in the first medium.

### Claim 194 (depends on 183)

The kit of claim 183, wherein said IL-2 in the second step is present at a concentration 50 to about 1500 IU/mL in the second medium.

### Claim 195 (depends on 183)

The kit of claim 183, wherein said second medium additionally comprises one or more of fetal calf serum (FCS), transferrin, insulin, ethanolamine, oleic acid, linoleic acid, palmitic acid, bovine serum albumin (BSA) and phytohemagglutinin.

### Claim 196 (depends on 183)

The kit of claim 183, wherein the hematopoietic stem or progenitor cells are CD34+.

### Claim 197 (depends on 183)

The kit of claim 183, wherein the hematopoietic stem or progenitor cells comprise hematopoietic stem or progenitor cells from human placental perfusate and hematopoietic stem or progenitor cells from umbilical cord, wherein said placental perfusate and said umbilical cord blood are from the same placenta.

### Claim 198 (depends on 183)

The kit of claim 183, wherein the feeder cells in step (b) comprise mitomycin C-treated peripheral blood mononuclear cells (PBMC), K562 cells or tissue culture-adherent stem cells.

### Claim 199 (depends on 183)

The kit of claim 183, wherein the NK cells are CD3−CD56+CD16−.

### Claim 200 (depends on 199)

The kit of claim 199, wherein the NK cells are additionally CD94+CD117+.

### Claim 201 (depends on 199)

The kit of claim 199, wherein the NK cells are additionally CD161−.

### Claim 202 (depends on 199)

The kit of claim 199, wherein the NK cells are additionally NKG2D+.

### Claim 203 (depends on 199)

The kit of claim 199, wherein the NK cells are additionally NKp46+.

### Claim 204 (depends on 199)

The kit of claim 199, wherein the NK cells are additionally CD226+.

### Claim 205 (depends on 178, 179)

The kit of claim 178 or 179, wherein the TSPNK cells are produced by a process comprising:
(a) culturing hematopoietic stem cells or progenitor cells in a first medium comprising Flt3L, TPO, SCF, IL-7, G-CSF, IL-6 and GM-CSF;
(b) subsequently culturing said cells in a second medium comprising Flt3L, SCF, IL-15, and IL-7, IL-17 and IL-15, G-CSF, IL-6 and GM-CSF; and
(c) subsequently culturing said cells in a third medium comprising SCF, IL-15, IL-7, IL-2, G-CSF, IL-6 and GM-CSF.

### Claim 206 (depends on 205)

The kit of claim 205, wherein the duration of culturing step (a) is 7-9 days, wherein the duration of culturing step (b) is 5-7 days, and wherein the duration of culturing step (c) is 5-9 days.

### Claim 207 (depends on 205)

The kit of claim 205, wherein the duration of culturing step (a) is 7-9 days, wherein the duration of culturing step (b) is 5-7 days, and wherein the duration of culturing step (c) is 21-35 days.

### Claim 208 (depends on 205, 206)

The kit of claim 205, 206, or 207 wherein the hematopoietic stem or progenitor cells used in the process are CD34+.

### Claim 209 (depends on 205, 206)

The kit of claim 205, 206, or 207 wherein the hematopoietic stem or progenitor cells comprise hematopoietic stem or progenitor cells from human placental perfusate and hematopoietic stem or progenitor cells from umbilical cord, wherein said placental perfusate and said umbilical cord blood are from the same placenta.

### Claim 210 (depends on 205, 206, 207, 208, 209)

The kit of any one of claims 205-209, wherein CD34− cells comprise more than 80% of the TSPNK cells at the end of step (a).

### Claim 211 (depends on 205, 206, 207, 208, 209, 210)

The kit of any one of claims 205-210, wherein the TSPNK cells comprise no more than 40% CD3− CD56+ cells.

### Claim 212 (depends on 205, 206, 207, 208, 209, 210, 211)

The kit of any one of claims 205-211, wherein the TSPNK cells comprise cells which are CD52+ CD117+.

### Claim 213 (depends on 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The kit of any one of claims 148-175, wherein the NK cells are produced by a process comprising:
(a) culturing hematopoietic stem or progenitor cells in a first medium comprising a stem cell mobilizing agent and thrombopoietin (Tpo) to produce a first population of cells;
(b) culturing the first population of cells in a second medium comprising a stem cell mobilizing agent and interleukin-15 (IL-15), and lacking Tpo, to produce a second population of cells; and
(c) culturing the second population of cells in a third medium comprising IL-2 and IL-15, and lacking a stem cell mobilizing agent and LMWH, to produce a third population of cells;
wherein the third population of cells comprises natural killer cells that are CD56+, CD3−, CD16− or CD16+, and CD94+ or CD94−, and wherein at least 80% of the natural killer cells are viable.

### Claim 214 (depends on 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213)

The kit of any one of claims 147-213, wherein the subject is a human.
